ストックスクリーナーアプリを入手
3.345
7.08%
-0.255
前日終値:
$3.60
開ける：
$3.46
24時間の取引高:
46,833
Relative Volume:
1.34
時価総額：
$18.01M
収益：
-
当期純損益:
$-2.17M
株価収益率:
-0.1929
EPS:
-17.3434
ネットキャッシュフロー:
$-4.82M
1週間 パフォーマンス:
+1.06%
1か月 パフォーマンス:
-15.95%
6か月 パフォーマンス:
+20.76%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$3.1101
$3.46
1週間の範囲:
$3.09
$3.60
52週間の値動き範囲:
$1.8299
$6.48
Newcelx Ltd Stock (NCEL) Company Profile
Compare NCEL vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NCEL
Newcelx Ltd
|
3.345 | 17.93M | 0 | -2.17M | -4.82M | -17.34 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Newcelx Ltd (NCEL) 最新ニュース
NewcelX Ord Shs (NCEL) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
NewcelX appoints diabetes researcher Ricordi to advisory board By Investing.com - Investing.com Nigeria
Press Release: NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing - Moomoo
NewcelX Announces $1.4 Million Private Placement at 20% Premium to Market to Advance NCEL-101 for Type 1 Diabetes - Quiver Quantitative
NewcelX Ltd. (NCEL) Edges Higher as Stock Tests Key Resistance at $3.70Post-Earnings Moves - dars.gov.et
NewcelX Ord Shs (NCEL) Valuation: PE, PB & Fair Value Analysis - TradingKey
NewcelX Ord Shs (NCEL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NewcelX Ord Shs (NCEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NewcelX Ord Shs (NCEL) Income Statement - TradingKey
NewcelX Ord Shs (NCEL) Balance Sheet - TradingKey
NewcelX Ord Shs (NCEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NewcelX Ord Shs (NCEL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NewcelX Ord Shs (NCEL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NCEL|NewcelX Ord Shs|Price:3.755|Chg%:-0.070 - TradingKey
NewcelX Ord Shs (NCEL) Cash Flow - TradingKey
NewcelX Ltd. Revenue Breakdown – NASDAQ:NCEL - TradingView
NewcelX (NCEL) Secures Patent for Innovative Technology - GuruFocus
NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio - The Manila Times
NewcelX Ltd. (NCEL) Holds Near $3.98 Support Zone After Modest DeclineRip Sell Trade - dars.gov.et
Laidlaw Initiates NewcelX(NCEL.US) With Buy Rating, Announces Target Price $23 - Moomoo
NCEL Initiated Coverage by Laidlaw & Co. -- Price Target Announced at $23 - GuruFocus
Laidlaw initiates NewcelX stock with buy rating on diabetes therapy - Investing.com
NLSP Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
NewcelX Strengthens Diabetes Push With Appointment of Leading Transplant Pioneer Camillo Ricordi - TipRanks
NewcelX appoints diabetes researcher Ricordi to advisory board - Investing.com
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board - The Manila Times
NewcelX appoints diabetes research pioneer Dr. Camillo Ricordi to boost Type 1 diabetes therapy development. - Pluang
NewcelX Appoints Diabetes Research Leader Camillo Ricordi to Scientific Advisory Board Following FDA Pre-IND Milestone - Quiver Quantitative
Enterprise value to EBIT forward of NewcelX Ltd. – BOATS:NCEL - TradingView
Enterprise value to revenue forward of NewcelX Ltd. – NASDAQ:NCEL - TradingView
Enterprise value to EBITDA forward of NewcelX Ltd. – NASDAQ:NCEL - TradingView
NCELNewcelX Ltd Volatility & Greeks - Finviz
NewcelX Ltd. (NCEL) Holds Steady at $3.85 as Traders Eye Key ResistanceInsider Buying Alerts - dars.gov.et
Price to book forward of NewcelX Ltd. – NASDAQ:NCEL - TradingView
NCEL Should I Buy - Intellectia AI
Newcelx Announces Successful FDA Pre-Ind Meet - Moomoo
NewcelX Wins FDA Backing to Advance NCEL-101 Toward Type 1 Diabetes Trials - theglobeandmail.com
NewcelX receives FDA feedback on type 1 diabetes therapy plan - Investing.com
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes - The Manila Times
NewcelX receives FDA feedback on type 1 diabetes therapy plan By Investing.com - Investing.com India
NewcelX Announces Successful FDA Pre-IND Meeting for NCEL-101 Type 1 Diabetes Program - Quiver Quantitative
NewcelX Ltd. Announces Successful FDA Pre-IND Meeting With Clear Path Forward For NCEL-101 Toward Starting Clinical Trials For Type 1 Diabetes - marketscreener.com
NewcelX Ltd. (NCEL) Gains 2.72%: Approaching Key Resistance at $3.96IPO Entry Watch - po-news-eg.net
NewcelX Shareholders Approve All Proposals at June 30 Annual Meeting - TipRanks
Number of shareholders of NewcelX Ltd. – NASDAQ:NCEL - TradingView
Number of shareholders of NewcelX Ltd. – BOATS:NCEL - TradingView
NewcelX Ltd. Actuals & Estimates (NASDAQ:NCEL) - TradingView
NewcelX Ord Shs (NCEL) Institutional Confidence - TradingKey
[EFFECT] NewcelX Ltd. SEC Filing - Stock Titan
NewcelX Ord Shs (NCEL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Exclusive: NewcelX eyes accelerated 2026 execution for diabetes drug - MSN
Newcelx Ltd (NCEL) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):